Bill Amendment: IL HB3957 | 2023-2024 | 103rd General Assembly
NOTE: For additional amemendments please see the Bill Drafting List
Bill Title: GENERIC DRUG PRICING FAIRNESS
Status: 2023-07-28 - Public Act . . . . . . . . . 103-0367 [HB3957 Detail]
Download: Illinois-2023-HB3957-House_Amendment_001.html
Bill Title: GENERIC DRUG PRICING FAIRNESS
Status: 2023-07-28 - Public Act . . . . . . . . . 103-0367 [HB3957 Detail]
Download: Illinois-2023-HB3957-House_Amendment_001.html
| |||||||
| |||||||
| |||||||
1 | AMENDMENT TO HOUSE BILL 3957
| ||||||
2 | AMENDMENT NO. ______. Amend House Bill 3957 by replacing | ||||||
3 | everything after the enacting clause with the following:
| ||||||
4 | "Section 1. Short title. This Act may be cited as the | ||||||
5 | Pharmaceutical and Health Affordability: Restrictions on | ||||||
6 | Manufacturers' Amoral Behavior through Reasonable Oversight | ||||||
7 | Act.
| ||||||
8 | Section 2. Legislative Findings. | ||||||
9 | (a) The General Assembly finds that public reports by | ||||||
10 | Congress and the news media have
demonstrated the devastating | ||||||
11 | impact that increasing drug prices can have on the
60% of | ||||||
12 | Americans and 90% of seniors that take prescription drugs. | ||||||
13 | (b) The General Assembly further finds that public reports | ||||||
14 | describe a repeated pattern and practice
of price gouging by | ||||||
15 | certain prescription drug manufacturers once they acquire the | ||||||
16 | ownership rights for a
new generic drug. |
| |||||||
| |||||||
1 | (c) The General Assembly further finds that price gouging | ||||||
2 | has forced patients to choose between
copayments exceeding | ||||||
3 | tens of thousands of dollars per year and risking their health | ||||||
4 | to find a more
affordable drug. | ||||||
5 | (d) The General Assembly further finds that this choice | ||||||
6 | has led patients to
delay or forgo necessary medications | ||||||
7 | creating greater health risks and complications. | ||||||
8 | (e) The General Assembly concludes that addressing | ||||||
9 | accessibility of these life-saving medications
is a matter of | ||||||
10 | health, safety, and welfare for the People of the State of | ||||||
11 | Illinois.
| ||||||
12 | Section 5. Definitions. As used in this Act: | ||||||
13 | "Essential off-patent or generic drug" means any | ||||||
14 | prescription drug sold within the State: | ||||||
15 | (1) for which all exclusive marketing rights, if any, | ||||||
16 | granted under the Federal Food, Drug, and Cosmetic Act, | ||||||
17 | Section 351 of the federal Public Health Service Act, and | ||||||
18 | federal patent law have expired; | ||||||
19 | (2) that appears on the model list of essential | ||||||
20 | medicines most recently adopted by the World Health | ||||||
21 | Organization or that has been designated by the United | ||||||
22 | States Secretary of Health and Human Services as an | ||||||
23 | essential medicine due to its efficacy in treating a | ||||||
24 | life-threatening health condition or a chronic health | ||||||
25 | condition that substantially impairs an individual's |
| |||||||
| |||||||
1 | ability to engage in activities of daily living; and | ||||||
2 | (3) that is actively manufactured and marketed for | ||||||
3 | sale in the United States by 3 or fewer manufacturers. | ||||||
4 | "Essential off-patent or generic drug" includes any | ||||||
5 | drug-device combination product used for the delivery of a | ||||||
6 | drug for which all exclusive marketing rights, if any, granted | ||||||
7 | under the Federal Food, Drug, and Cosmetic Act, Section 351 of | ||||||
8 | the federal Public Health Service Act, and federal patent law | ||||||
9 | have expired. | ||||||
10 | "Manufacturer" has the meaning provided in Section 15 of | ||||||
11 | the Wholesale Drug Distribution Licensing Act. Manufacturer" | ||||||
12 | does not include an entity operating as a wholesale drug | ||||||
13 | distributor as defined in Section 15 of the Wholesale Drug | ||||||
14 | Distribution Licensing Act. | ||||||
15 | "Price gouging" means an unconscionable increase in a | ||||||
16 | prescription drug's price that: | ||||||
17 | (1) would result in the wholesale acquisition cost of | ||||||
18 | a 30-day supply of the essential off-patent or generic | ||||||
19 | drug exceeding $20 and would result in an increase in the | ||||||
20 | wholesale acquisition cost of the essential off-patent or | ||||||
21 | generic drug of: | ||||||
22 | (A) 30% or more within the preceding year; | ||||||
23 | (B) 50% or more within the preceding 3 years; or | ||||||
24 | (C) 75% or more within the preceding 5 years; | ||||||
25 | (2) is otherwise excessive and unduly burdens | ||||||
26 | consumers because of the importance of the essential |
| |||||||
| |||||||
1 | off-patent or generic drug to their health and because of | ||||||
2 | insufficient competition in the marketplace. | ||||||
3 | "Price gouging" does not include a price increase that can | ||||||
4 | be reasonably justified by: | ||||||
5 | (1) an increase in the cost of producing the essential | ||||||
6 | off-patent or generic drug; or | ||||||
7 | (2) the cost of appropriate expansion of access to the | ||||||
8 | essential off-patent or generic drug to promote public | ||||||
9 | health. | ||||||
10 | "State health plan" means the program of health benefits | ||||||
11 | under the State Employees Group Insurance Act of 1971. | ||||||
12 | "Wholesale acquisition cost" has the meaning provided in | ||||||
13 | 42 U.S.C. 1395w-3a. | ||||||
14 | "Wholesale drug distributor" has the meaning provided in | ||||||
15 | Section 15 of the Wholesale Drug Distribution Licensing Act.
| ||||||
16 | Section 10. Price gouging prohibited. | ||||||
17 | (a) A manufacturer or wholesale drug distributor shall not | ||||||
18 | engage in price gouging in the sale of an essential off-patent | ||||||
19 | or generic drug that is ultimately sold in Illinois. | ||||||
20 | It is not a violation of this Act for a wholesale | ||||||
21 | distributor to increase the price of an essential off-patent | ||||||
22 | or generic drug if the price increase is directly attributable | ||||||
23 | to an increase in the wholesale acquisition cost for the | ||||||
24 | essential off-patent or generic drug imposed on the wholesale | ||||||
25 | drug distributor by the manufacturer of the drug. |
| |||||||
| |||||||
1 | For the purpose of the enforcement of this Act: | ||||||
2 | (1) the Director of Healthcare and Family Services | ||||||
3 | shall notify the Attorney General of any increase in the | ||||||
4 | price of any essential off-patent or generic drug under | ||||||
5 | the Medical Assistance Program under Section V of the | ||||||
6 | Illinois Public Aid Code that amounts to price gouging; | ||||||
7 | and | ||||||
8 | (2) the Director of Central Management Services shall | ||||||
9 | notify the Attorney General of any increase in the price | ||||||
10 | of any essential off-patent or generic drug under the | ||||||
11 | State health plan that amounts to price gouging. | ||||||
12 | (b) If the Attorney General has reason to believe that a | ||||||
13 | manufacturer or wholesale drug distributor of an essential | ||||||
14 | off-patent or generic drug has violated this Act, then the | ||||||
15 | Attorney General shall send a notice to the manufacturer or | ||||||
16 | the wholesale drug distributor requesting a statement: | ||||||
17 | (1) itemizing the components of the cost of producing | ||||||
18 | the essential off-patent or generic drug; | ||||||
19 | (2) identifying the circumstances and timing of an | ||||||
20 | increase in materials or manufacturing costs that caused | ||||||
21 | an increase in the wholesale acquisition cost of the | ||||||
22 | essential off-patent or generic drug within the 5-year | ||||||
23 | period preceding the date of the price increase; | ||||||
24 | (3) identifying the circumstances and timing of any | ||||||
25 | expenditures made by the manufacturer to expand access to | ||||||
26 | the essential off-patent or generic drug and explaining |
| |||||||
| |||||||
1 | any improvement in public health associated with those | ||||||
2 | expenditures; | ||||||
3 | (4) identifying any communications with competitors of | ||||||
4 | distributors about that drug and any price
changes; the | ||||||
5 | request for a statement shall serve as a litigation hold | ||||||
6 | regarding documents and communications
about that drug; | ||||||
7 | and | ||||||
8 | (5) providing any other information that the | ||||||
9 | manufacturer or wholesale drug distributor believes to be | ||||||
10 | relevant to a determination of whether a violation of this | ||||||
11 | Act has occurred. | ||||||
12 | Within 45 days after receipt of the request, the | ||||||
13 | manufacturer or wholesale drug distributor shall submit the | ||||||
14 | statement to the Attorney General. | ||||||
15 | To accomplish the objectives and carry out the duties | ||||||
16 | prescribed in this Act, the Attorney General may issue | ||||||
17 | subpoenas or examine under oath any person to determine | ||||||
18 | whether a manufacturer or wholesale drug distributor has | ||||||
19 | violated this Act. | ||||||
20 | (c) Upon petition of the Attorney General, a circuit court | ||||||
21 | may issue an order: | ||||||
22 | (1) compelling a manufacturer or a wholesale drug | ||||||
23 | distributor: | ||||||
24 | (A) to provide a statement required under | ||||||
25 | subsection (b); or | ||||||
26 | (B) to produce specific records or other documents |
| |||||||
| |||||||
1 | requested by the Attorney General that may be relevant | ||||||
2 | to a determination of whether a violation of this Act | ||||||
3 | has occurred; | ||||||
4 | (2) restraining or enjoining a violation of this Act; | ||||||
5 | (3) restoring to any consumer, including a third-party | ||||||
6 | payor, any money acquired as a result of a price increase | ||||||
7 | that violates this Act; | ||||||
8 | (4) requiring a manufacturer or wholesale drug | ||||||
9 | distributor that has engaged in price gouging in the sale | ||||||
10 | of an essential off-patent or generic drug to make the | ||||||
11 | drug available to participants in the State health plan or | ||||||
12 | Medical Assistance Program under Section V of the Illinois | ||||||
13 | Public Aid Code for a period of up to one year at the price | ||||||
14 | at which the drug was made available to participants in | ||||||
15 | Illinois immediately before the violation of this Act; | ||||||
16 | (5) imposing a civil penalty of up to $10,000 per day | ||||||
17 | for each violation of this Act; | ||||||
18 | (6) providing for the Attorney General's recovery of | ||||||
19 | costs and disbursements incurred in
bringing an action | ||||||
20 | against a manufacturer found to be in violation of this | ||||||
21 | Act, including the costs of
investigation and reasonable | ||||||
22 | attorney's fees; or | ||||||
23 | (7) granting any other relief. | ||||||
24 | In response to any petition brought by the Attorney | ||||||
25 | General under this Section, a manufacturer or wholesale drug | ||||||
26 | distributor who is alleged to have violated this Act may not |
| |||||||
| |||||||
1 | assert as a defense that the manufacturer or wholesale drug | ||||||
2 | distributor did not directly sell a product to a consumer | ||||||
3 | residing in Illinois. | ||||||
4 | (d) Any financial information provided by a manufacturer | ||||||
5 | or a wholesale drug distributor to the Attorney General in | ||||||
6 | accordance with this Section may not be disclosed to the | ||||||
7 | public by the Attorney General. The financial information, | ||||||
8 | while in the possession of the Attorney General, shall be | ||||||
9 | exempt from disclosure by the Attorney General under the | ||||||
10 | Freedom of Information Act. Notwithstanding the other | ||||||
11 | provisions of this subsection, if it appears to the Attorney | ||||||
12 | General that a manufacturer or wholesale drug distributor has | ||||||
13 | engaged in or is engaging in any practice declared to be in | ||||||
14 | violation of this Act and that legal proceedings would be in | ||||||
15 | the public interest, then the Attorney General may disclose | ||||||
16 | any financial information provided in accordance with this | ||||||
17 | Section in support of the filing of an action in the circuit | ||||||
18 | court.
| ||||||
19 | Section 99. Effective date. This Act takes effect January | ||||||
20 | 1, 2024.".
|